Immuneering appointed oncology commercialization veteran Grant Bogle to its board as it pushes atebimetinib through late-stage development. The move adds more t

Immuneering appointed oncology commercialization veteran Grant Bogle to its board as it pushes atebimetinib through late-stage development. The move adds more than 40 years of sector experience as the company builds on recent RAS-mutant cancer data.